RxSight (RXST) director receives 37,037 RSUs, now directly holds 85,183 shares
Rhea-AI Filing Summary
Tammenoms Bakker Juliet reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. board member Juliet Tammenoms Bakker reported an equity compensation grant in the form of restricted stock units. She received 37,037 RSUs, each representing one share of RxSight common stock, at a price of $0.00 per share, increasing her direct holdings to 85,183 shares.
The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to her continued service as an Outside Director. She also has 1,548 shares held indirectly in a trust, where she may share voting and investment power but disclaims beneficial ownership beyond her economic interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 37,037 shares
Net Buy
2 txns
Insider
Tammenoms Bakker Juliet
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 37,037 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 85,183 shares (Direct);
Common Stock — 1,548 shares (Indirect, See footnote)
Footnotes (3)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
- F2. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
- F3. These securities are held by a trust. The Reporting Person, a member of the Issuer's board of directors, is the Investment Trustee of such trust and may be deemed to share voting, investment and dispositive power with respect to such securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Key Figures
RSU grant size: 37,037 RSUs
Grant price per share: $0.00 per share
Direct holdings after grant: 85,183 shares
+3 more
6 metrics
RSU grant size
37,037 RSUs
Restricted stock units granted on June 17, 2026
Grant price per share
$0.00 per share
Price for RSU award to Outside Director
Direct holdings after grant
85,183 shares
Common stock directly held following RSU award
Indirect trust holdings
1,548 shares
Common stock held indirectly via trust with shared powers
Vesting condition
100% cliff vest
Vests on earlier of 1-year from June 17, 2026 or next annual meeting
Vesting service requirement
Continued Outside Director service
Must remain an Outside Director through vesting date
Key Terms
restricted stock unit ("RSU"), Outside Director, 2021 Equity Incentive Plan, beneficial ownership, +1 more
5 terms
restricted stock unit ("RSU") financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock."
Outside Director financial
"Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date"
2021 Equity Incentive Plan financial
"Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date"
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What did RxSight (RXST) director Juliet Tammenoms Bakker receive in this Form 4?
She received a grant of 37,037 restricted stock units (RSUs). Each RSU represents a contingent right to one share of RxSight common stock, awarded as equity compensation at $0.00 per share, rather than a cash purchase in the open market.
What is the vesting schedule for Juliet Tammenoms Bakker’s RxSight RSUs?
All RSUs vest in a single installment. They vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders, provided she continues serving as an Outside Director through the applicable vesting date.
Are Juliet Tammenoms Bakker’s RxSight RSUs an open-market purchase?
No, the RSUs are a grant, not a market trade. The 37,037 RSUs were awarded at $0.00 per share as director equity compensation, classified as a grant, award, or other acquisition rather than a buy transaction in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
